Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Effects of anti-VEGF treatment on the recovery of the developing retina following oxygen-induced retinopathy.

Tokunaga CC, Mitton KP, Dailey W, Massoll C, Roumayah K, Guzman E, Tarabishy N, Cheng M, Drenser KA.

Invest Ophthalmol Vis Sci. 2014 Mar 28;55(3):1884-92. doi: 10.1167/iovs.13-13397.

PMID:
24550366
2.

Retinal vascular rescue of oxygen-induced retinopathy in mice by norrin.

Tokunaga CC, Chen YH, Dailey W, Cheng M, Drenser KA.

Invest Ophthalmol Vis Sci. 2013 Jan 9;54(1):222-9. doi: 10.1167/iovs.12-10127.

PMID:
23188723
3.

Effect of VEGF trap on normal retinal vascular development and oxygen-induced retinopathy in the dog.

Lutty GA, McLeod DS, Bhutto I, Wiegand SJ.

Invest Ophthalmol Vis Sci. 2011 Jun 8;52(7):4039-47. doi: 10.1167/iovs.10-6798.

7.

Local injection of receptor tyrosine kinase inhibitor MAE 87 reduces retinal neovascularization in mice.

Unsoeld AS, Junker B, Mazitschek R, Martin G, Hansen LL, Giannis A, Agostini HT.

Mol Vis. 2004 Jul 15;10:468-75.

8.

RhoA activation and effect of Rho-kinase inhibitor in the development of retinal neovascularization in a mouse model of oxygen-induced retinopathy.

Fang X, Ueno M, Yamashita T, Ikuno Y.

Curr Eye Res. 2011 Nov;36(11):1028-36. doi: 10.3109/02713683.2011.593110.

PMID:
21999228
10.

Aflibercept in wet AMD: specific role and optimal use.

Semeraro F, Morescalchi F, Duse S, Parmeggiani F, Gambicorti E, Costagliola C.

Drug Des Devel Ther. 2013 Aug 5;7:711-22. doi: 10.2147/DDDT.S40215. Review.

11.

Propranolol inhibition of β-adrenergic receptor does not suppress pathologic neovascularization in oxygen-induced retinopathy.

Chen J, Joyal JS, Hatton CJ, Juan AM, Pei DT, Hurst CG, Xu D, Stahl A, Hellstrom A, Smith LE.

Invest Ophthalmol Vis Sci. 2012 May 17;53(6):2968-77. doi: 10.1167/iovs.12-9691.

12.

The dipeptide Arg-Gln inhibits retinal neovascularization in the mouse model of oxygen-induced retinopathy.

Neu J, Afzal A, Pan H, Gallego E, Li N, Li Calzi S, Caballero S, Spoerri PE, Shaw LC, Grant MB.

Invest Ophthalmol Vis Sci. 2006 Jul;47(7):3151-5.

PMID:
16799062
13.

Role of the adrenergic system in a mouse model of oxygen-induced retinopathy: antiangiogenic effects of beta-adrenoreceptor blockade.

Ristori C, Filippi L, Dal Monte M, Martini D, Cammalleri M, Fortunato P, la Marca G, Fiorini P, Bagnoli P.

Invest Ophthalmol Vis Sci. 2011 Jan 5;52(1):155-70. doi: 10.1167/iovs.10-5536.

PMID:
20739470
14.

The neurovascular relation in oxygen-induced retinopathy.

Akula JD, Mocko JA, Benador IY, Hansen RM, Favazza TL, Vyhovsky TC, Fulton AB.

Mol Vis. 2008;14:2499-508.

15.

Localization of VEGF receptor-2 (KDR/Flk-1) and effects of blocking it in oxygen-induced retinopathy.

McLeod DS, Taomoto M, Cao J, Zhu Z, Witte L, Lutty GA.

Invest Ophthalmol Vis Sci. 2002 Feb;43(2):474-82.

PMID:
11818393
16.

Retinal vascular endothelial growth factor (VEGF) mRNA expression is altered in relation to neovascularization in oxygen induced retinopathy.

Donahue ML, Phelps DL, Watkins RH, LoMonaco MB, Horowitz S.

Curr Eye Res. 1996 Feb;15(2):175-84.

PMID:
8670726
17.

Captopril and vascular endothelial growth factor in a mouse model of retinopathy.

Higgins RD, Yan Y, Geng Y, Sharma J, Barr SM.

Curr Eye Res. 2003 Aug;27(2):123-9.

PMID:
14632165
18.

Expression of pro- and anti-angiogenic isoforms of VEGF in the mouse model of oxygen-induced retinopathy.

Zhao M, Shi X, Liang J, Miao Y, Xie W, Zhang Y, Li X.

Exp Eye Res. 2011 Dec;93(6):921-6. doi: 10.1016/j.exer.2011.10.013.

PMID:
22067127
19.

Intravitreal anti-VEGF therapy blocks inflammatory cell infiltration and re-entry into the circulation in retinal angiogenesis.

Nakao S, Arima M, Ishikawa K, Kohno R, Kawahara S, Miyazaki M, Yoshida S, Enaida H, Hafezi-Moghadam A, Kono T, Ishibashi T.

Invest Ophthalmol Vis Sci. 2012 Jun 28;53(7):4323-8. doi: 10.1167/iovs.11-9119.

PMID:
22661475
20.

Systemic rapamycin inhibits retinal and choroidal neovascularization in mice.

Dejneka NS, Kuroki AM, Fosnot J, Tang W, Tolentino MJ, Bennett J.

Mol Vis. 2004 Dec 22;10:964-72.

Items per page

Supplemental Content

Support Center